Drugs / G-CSF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03579875 Background | Nov 2018 → Jan 2027 expected | Fanconi anemia, TCR-alpha-beta-positive T-cell deficiency, bone marrow failure syndrome, dyskeratosis congenita +2 | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03579875 ↗ |
| Route | Intravenous | “5mcg/kg per day IV” NCT03579875 ↗ |